BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression

por Mandel, Ilana, Haves Ziv, Dana, Goldshtein, Ilana, Peretz, Tsuri, Alishekevitz, Dror, Fridman Dror, Anna, Hakim, Motti, Hashmueli, Sharon, Friedman, Itay, Sapir, Yair, Greco, Rita, Qu, Hongjing, Nestle, Frank, Wiederschain, Dmitri, Pao, Lily, Sharma, Sharad, Ben Moshe, Tehila
Publicado 2022

Donor cell leukemia: is reappearance of gene mutations in donor cells more than an incidental phenomenon?

por Gabay, Tal Shahar, Chapal-Ilani, Noa, Moskovitz, Yoni, Biezuner, Tamir, Oron, Barak, Brilon, Yardena, Fridman-Dror, Anna, Sabah, Rawan, Balicer, Ran, Tanay, Amos, Mendelson-Cohen, Netta, Dann, Eldad J., Fineman, Riva, Kaushansky, Nathali, Yehudai-Reshef, Shlomit, Zuckerman, Tsila, Shlush, Liran I.
Publicado 2020